Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Lynda Spelman, Diana Rubel, Alan Brnabic, Nicole Burkhardt, Elisabeth Riedl & Peter Foley. (2022) A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis. Journal of Dermatological Treatment 33:1, pages 329-335.
Read now
Read now
Andrew Blauvelt, Mark Lomaga, Russel Burge, Baojin Zhu, Wei Shen, David Shrom, Martin Dossenbach & Andreas Pinter. (2020) Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial. Journal of Dermatological Treatment 31:2, pages 141-146.
Read now
Read now
Boni E. Elewski, Lluís Puig, Margaret Mordin, Isabelle Gilloteau, Bintu Sherif, Todd Fox, Ari Gnanasakthy, Charis Papavassilis & Bruce E. Strober. (2017) Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab. Journal of Dermatological Treatment 28:6, pages 492-499.
Read now
Read now
Articles from other publishers (9)
Andrew Blauvelt, Melinda Gooderham, Christopher E. M. Griffiths, April W. Armstrong, Baojin Zhu, Russel Burge, Gaia Gallo, Jiaying Guo, Alyssa Garrelts & Mark Lebwohl. (2022) Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-Analysis. Dermatology and Therapy 12:3, pages 727-740.
Crossref
Crossref
Georgios Kokolakis, Kasper Vadstrup, Jes B. Hansen & Jose Manuel Carrascosa. (2022) Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis. Dermatology 238:4, pages 620-629.
Crossref
Crossref
K. Reich, J.B. Hansen, L. Puig, M.P. Konstantinou & R.B. Warren. (2021) Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE‐2 and AMAGINE‐3. Journal of the European Academy of Dermatology and Venereology 35:10, pages 2034-2044.
Crossref
Crossref
R.B. Warren, J.B. Hansen, K. Reich, C. Paul & L. Puig. (2020) Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE‐2 and ‐3. Journal of the European Academy of Dermatology and Venereology 35:2, pages 450-457.
Crossref
Crossref
Andrew BlauveltRussel BurgeWilliam MalatestinicAlan BrnabicJiaying GuoManju JanardhananBaojin Zhu. (2021) Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review. Journal of Managed Care & Specialty Pharmacy 27:1, pages 84-94.
Crossref
Crossref
Richard B. Warren, Melinda Gooderham, Russel Burge, Baojin Zhu, David Amato, Karen Huayu Liu, David Shrom, Jiaying Guo, Alan Brnabic & Andrew Blauvelt. (2020) Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. Journal of the American Academy of Dermatology 82:5, pages 1138-1149.
Crossref
Crossref
José-María Ortiz-Salvador, Martina Saneleuterio-Temporal, Jorge Magdaleno-Tapial, Manel Velasco-Pastor, Conrad Pujol-Marco, Antonio Sahuquillo-Torralba, Almudena Mateu-Puchades, Gerard Pitarch-Bort, Juan-Ignacio Marí-Ruiz, Javier Mataix-Díaz, Encarna Montesinos-Villaescusa, Julia Miralles-Botella, Laura García-Fernández, Antonio Martorell-Calatayud, Isabel Belinchón-Romero, José-Luis Sánchez-Carazo & Amparo Pérez-Ferriols. (2019) A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients. Journal of the American Academy of Dermatology 81:2, pages 427-432.
Crossref
Crossref
Lluís Puig, Matthias Augustin, Andrew Blauvelt, Alice B. Gottlieb, Ron Vender, Neil J. Korman, Diamant Thaçi, Yang Zhao, Isabelle Gilloteau, Bintu Sherif, Nicole Williams, Adriana Guana & Mark G. Lebwohl. (2018) Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. Journal of the American Academy of Dermatology 78:4, pages 741-748.
Crossref
Crossref
Bruce Strober, Alice B. Gottlieb, Bintu Sherif, Patrick Mollon, Isabelle Gilloteau, Lori McLeod, Todd Fox, Margaret Mordin, Ari Gnanasakthy, Charis Papavassilis & Mark G. Lebwohl. (2017) Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. Journal of the American Academy of Dermatology 76:4, pages 655-661.
Crossref
Crossref